Specilid (Nimesulide) is commonly associated with the management of acute pain and primary dysmenorrhoea. This medication may assist with short-term symptomatic relief for clinical situations characterized by pain, inflammation, and fever. Its use centers on alleviating the burden of distressing manifestations across several common therapeutic domains, including painful conditions such as osteoarthritis flares, discomfort after minor procedures like dental extractions, and pain from acute musculoskeletal injuries like sprains and tendinitis.

---

Key Therapeutic Focus

The primary therapeutic benefit is considered relevant for supporting the patient during episodes where symptoms become more noticeable. This involves addressing groups of symptoms that may appear suddenly or intensify over time, and contributes to easing the overall symptom load.

“Specilid is applied in addressing symptoms related to inflammatory or irritative states that create noticeable physiological strain.”

This support may assist with maintaining a sense of stability when symptoms are more noticeable, and supports the patient during difficult episodes by easing distress. It is commonly used to help with managing the combination of fever and localized inflammatory symptoms, such as painful earaches or sore throats.

Quick Fact: Supportive relief for symptoms related to Acute Pain and Inflammatory States

Who Can and Cannot Use Specilid?

Population eligibility for Specilid (Nimesulide) is strictly defined by regulatory documents, establishing clear patient criteria and absolute prohibitions based on organ function, age, and existing medical conditions.

Eligibility Status	Official Regulatory Rule
Allowed Age	Adults and adolescents (12 years and older). Children under 12 years are contraindicated.
Organ Function	Contraindicated in any degree of hepatic impairment or severe renal impairment (creatinine clearance less than 30 mL/min).

Absolute Contraindications

The medicine must not be used by individuals with the following conditions, as they are formally contraindicated:

• A history of hepatotoxic reactions to nimesulide.
• Severe heart failure, active gastric or duodenal ulcer, or active bleeding (e.g., severe coagulation disorders).
• Known hypersensitivity to Specilid or other non-steroidal anti-inflammatory drugs (NSAIDs).
• Fever and/or flu-like symptoms.
• Alcoholism or drug addiction.

Special Population Restrictions

The medicine is contraindicated during the third trimester of pregnancy and while breastfeeding. It is not recommended for women attempting to conceive. Use requires caution in the elderly (clinical monitoring is advisable) and in patients with mild to moderate renal impairment, or pre-existing cardiovascular and gastrointestinal conditions.

Specilid Interactions with other medicines and products

Specilid (Nimesulide), as a Non-Steroidal Anti-Inflammatory Drug (NSAID), has the potential to interact with other medications, potentially altering their effects or increasing the risk of adverse reactions.

Pharmacodynamic Interactions

• Other NSAIDs and Salicylates (including Aspirin): Concomitant use with other NSAIDs, including cyclooxygenase-2 selective inhibitors, or anti-inflammatory doses of acetylsalicylic acid (aspirin), should be avoided due to the increased risk of gastrointestinal (GI) side effects, such as ulceration or bleeding.
• Corticosteroids: Taking Specilid with corticosteroids increases the risk of GI ulceration or bleeding.
• Anticoagulants: Specilid can enhance the effects of anticoagulants, such as Warfarin, raising the risk of bleeding complications. Patients on this combination require careful monitoring of coagulation parameters.
• Antiplatelet Agents and Selective Serotonin Reuptake Inhibitors (SSRIs): The risk of GI bleeding is also increased when Specilid is used with antiplatelet agents like low-dose aspirin or SSRIs.
• Diuretics, Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors), and Angiotensin II Antagonists (AIIA): Specilid may reduce the effectiveness of these medications. In patients with compromised renal function (e.g., dehydrated or elderly patients), the combined use with ACE inhibitors or AIIAs can worsen kidney function.

Pharmacokinetic Interactions

• Lithium: Specilid may reduce the clearance of Lithium, leading to increased plasma levels and a greater risk of toxicity. Lithium levels must be closely monitored.
• Furosemide: Specilid can temporarily decrease the diuretic and sodium excretion effects of Furosemide.

Specilid is metabolized by the enzyme CYP2C9 in the liver, meaning it has the potential to interact with other drugs metabolized by this enzyme. Always inform your healthcare provider about all medicines, over-the-counter products, and herbal supplements you are taking.

The molecule's mechanism of action involves a multi-target action to modulate enzyme activity and cellular processes. The molecule acts across enzymatic activity, cellular stress pathways, and central thermoregulatory processes.

Enzymatic Control Over Inflammatory Mediators

The primary action involves preferential inhibition of the Cyclooxygenase-2 ( COX-2) isoenzyme. COX-2 is the catalyst for synthesizing Prostaglandins, which are local chemical mediators. By limiting the production of these primary mediators at the molecular level, the action limits chemical sensitization of peripheral nociceptive fibers and restricts localized fluid accumulation ( edema).

Cellular Protection and Multi-Target Modulation

Beyond its effect on COX-2, the molecule exerts complementary actions by directly scavenging Reactive Oxygen Species ( ROS) and inhibiting the activity of destructive enzymes like Human Neutrophil Elastase ( HNE). These interactions address molecular changes associated with ROS production and enzymatic degradation, modulating the activity of the localized inflammatory environment.

️ Central Regulation of Core Body Temperature

The molecule engages mechanisms that regulate the hypothalamic thermoregulatory set point in the central nervous system ( CNS). By reducing Prostaglandin levels in this brain region, the mechanism suppresses the central molecular process that elevates the thermoregulatory set point. This action results in a reversal of the elevated thermoregulatory set point.

How to Use Specilid: Official Administration Guidelines

The usage of Specilid (Nimesulide) is governed by regulatory parameters which define the methods, dosing, and time limits for its administration. This information is based on official prescribing guidance.

---

Administration Routes and Forms

Specilid is formally approved for oral administration via tablets or granules for systemic treatment, and for topical administration as a gel (typically 3% w/w) for local application. Regional availability may include other forms, such as suppositories.

---

Standard Dosing and Frequency

Administration Type	Dose	Frequency	Maximum Course Duration
Oral (Systemic)	100 mg	Twice Daily (BID)	15 days
Topical (Gel)	Approx. 6-7 cm line of gel	2 to 3 times per day	7 to 15 days

The overarching principle for use is to administer the minimum effective dose for the shortest possible duration. The maximum daily oral intake must not exceed 200 mg.

---

Administration Conditions and Restrictions

Oral forms must be taken after a meal to meet official administration requirements. Systemic Specilid is contraindicated and not approved for use in children under 12 years of age or in patients with severe hepatic or renal impairment. No standard dosage adjustment is required for older adults or adolescents (12–18 years). The systemic form is reserved for use when other options have been deemed unsuitable, positioning it as a second-line treatment.

Research Evidence / Overview of Studies for Specilid

---

## Evidence for Use in Acute Pain and Inflammation

The research exploring Specilid's profile in conditions characterized by acute pain, such as musculoskeletal discomfort, has relied predominantly on short-term Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies included adults and adolescents (age 12 and older) and monitored the speed and reported changes in pain intensity over defined intervals. Comparative studies were used to monitor these parameters.

Studies observed responses over defined time intervals, and the findings described patterns observed in the study groups during the acute phase of symptoms. However, research provides insight into short-term changes only. The evidence record is structured around strict guidelines that limit use to short, acute episodes.

---

## Evidence for Use in Primary Dysmenorrhoea

Specilid was evaluated in studies related to primary dysmenorrhoea (menstrual pain) using specific Randomized Controlled Trials (RCTs). This research monitored patient-reported outcomes describing perceived discomfort in populations of adults and adolescents who were included in these studies. Regulatory assessments that have examined this evidence described the available data as consistent regarding the investigational goals for this specific, short-term use.

---

## Evidence Structure for Osteoarthritis Symptom Flares

Research has explored Specilid in conditions characterized by painful osteoarthritis symptom flares. The studies primarily utilized double-blind, multicenter trials, measuring outcomes reflecting daily functioning (e.g., WOMAC and Lequesne indices) alongside measurements of joint pain intensity in adult patients. Short-term trial data reported changes in pain and functional measures documented during the study period.

---

## Research Focus on Long-Term Outcomes and Follow-up

Analysis of the research suggests that a primary limitation shaping the evidence landscape is the structurally limited follow-up durations for continuous use, reflecting the mandated maximum 15-day treatment duration. Consequently, long-term changes are not fully established, and follow-up durations were limited in most of the core efficacy trials. Data for special groups, such as older adults or patients with specific comorbidities, are still emerging or remain insufficient, meaning the results apply only to the populations studied within these short-term trials. Furthermore, the drug’s lack of approval in several major countries limits the generalizability of findings.

Common questions about Specilid (FAQ)

Q: Does Specilid help with nerve pain?

Regulatory documents state that Specilid is indicated for the treatment of neuropathic pain, which is pain caused by damaged nerves. According to the official product information, it works by stabilizing nerve cells to reduce the sending of pain signals. Regulatory documents state that it is used to manage this type of persistent, chronic pain.

Q: Can I take Specilid if I have had kidney problems?

According to the official product information, patients with impaired kidney function may need special consideration when using Specilid. Regulatory information indicates that dosage adjustments may be necessary for people with impaired kidney function. This is because Specilid is primarily cleared from the body through the kidneys, and impairment may affect how the drug is processed.

Q: How long does it take for Specilid to start working?

Studies and official information indicate that the time it takes for a patient to notice the effect of Specilid can vary. Because treatment often starts with a lower dose that is gradually increased, it may take several weeks as the dose is often gradually adjusted. The full effect is not usually immediate due to this necessary titration process.

Q: Is it safe to drive while taking Specilid?

Official product information states that Specilid can cause side effects such as dizziness, sleepiness, or blurred vision. Regulatory documents caution that these side effects can impair the ability to perform skilled tasks. Official product information suggests caution, recommending patients assess their reaction to the medicine before driving or operating machinery.

Q: Is Specilid a type of opioid or narcotic?

Specilid is not classified as an opioid or narcotic medicine. According to official product information, it belongs to a class of drugs known as gabapentinoids. This medicine works on certain chemicals in the brain and nervous system in a way that is different from opioid pain relievers.

Storage Requirements

Specilid (Nimesulide) must be stored in compliance with regulatory mandates to ensure product stability. The required storage temperature is not exceeding 30 C, which corresponds to ambient or room temperature storage.

Protection is mandatory: the medicine must be kept in its original container or packaging to protect the contents from both light and moisture. The product should not be frozen.

Stability and Handling

For the granules for oral suspension, the product must be taken immediately after preparation or reconstitution; it cannot be stored for later use. For all forms of Specilid, the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Disposal must follow local regulatory procedures for medicinal products. Official instructions prohibit disposing of unused or expired Specilid via wastewater or household waste to prevent environmental contamination. The proper method is to discard the product according to authorized collection schemes.